Investing
FDA rejects Mesoblast’s cell therapy for bone marrow transplant complications
© Reuters. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo/File Photo
(Reuters) – The U.S. Food and Drug Administration had rejected Mesoblast (NASDAQ:)’s cell therapy for children under 12 years of age for treating a type of complication that occurs after a stem cell or bone marrow transplant, the company said on Thursday.
The health regulator required more data to support marketing approval for the company’s lead product remestemcel-L, Mesoblast said in a statement.
The rejection deals a blow to Mesoblast’s hopes for a potential launch of the therapy, especially after its fundraising efforts over the last two years.
The drug developer was seeking the FDA’s approval for a cell therapy to treat children with a type of graft versus host disease (GvHD), whose symptoms did not respond to standard steroid therapy or developed recurrence while continuing treatment.
There are no approved therapies in children for the condition in which the donor bone marrow or stem cells attack the recipient.
Read the full article here
Closing Your Business? Do It Before the New Year to Save Money
Why Irate Artists Leaked OpenAI’s AI Video Generator Sora
Friends’ ‘Scrappy’ Side Hustle Led to a $1 Million Product
Unlock Lasting Business Success by Instilling These 5 Family Values
BlackRock, Vanguard, State Street sued by Republican states over climate push By Reuters
This All-Access Pass to Learning Is Now $20 for Black Friday
How to Create a Routine That Balances Rest and Business Success
Apple Prepares a New AI-Powered Siri to Compete With ChatGPT
A Macy’s Employee Made Accounting Errors Worth $132 Million
Customers Want More Than Just a Product — Here’s How to Keep Up
Debt ceiling debate and its effect on the U.S. dollar
Debt ceiling default: Still no deal between parties
Stovall: If the U.S. defaults on its debt, all S&P 500 sectors will likely fall
What China's weaker-than-expected economy could mean for U.S. markets
A ‘Big Short’ investor sees financial disaster brewing in housing markets — again
-
Investing4 days agoThis All-Access Pass to Learning Is Now $20 for Black Friday
-
Passive Income4 days agoHow to Create a Routine That Balances Rest and Business Success
-
Side Hustles5 days agoApple Prepares a New AI-Powered Siri to Compete With ChatGPT
-
Side Hustles2 days agoA Macy’s Employee Made Accounting Errors Worth $132 Million
-
Passive Income5 days agoCustomers Want More Than Just a Product — Here’s How to Keep Up
-
Side Hustles6 days agoMIT Gives Free Tuition For Families Earning $200,000 or Less
-
Side Hustles4 days agoGift the Power of Language Learning with This Limited-Time Price on Babbel
-
Investing2 days agoFactbox-How Trump can overhaul US financial regulators when he takes office By Reuters